Why People Are Coming to Israel for PRRT to Treat Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy (PRRT) is a molecular targeted therapy used to treat neuroendocrine tumors (NETs). Over the last decade, this innovative treatment has been used to improve the prognoses of NET patients in Europe. It is now available at Sheba Medical Center in Israel.
What are NETs?
Neuroendocrine tumors, or NETs, are abnormal growths that form from endocrine or nervous system cells. NETs most often occur in the intestines, but they can be found in the pancreas, lungs, and other parts of the body. Cancerous NETs are rare but usually discovered at a later, progressive stage of the disease.
How Does PRRT work?
Neuroendocrine cells usually express receptors for a hormone called somatostatin. In PRRT, a cell-targeting protein (peptide) similar to somatostatin is combined with radioactive material to create a radiopeptide. The radiopeptides are injected into the vein and sent out into the bloodstream to seek out and bind to the somatostatin receptors on the NET cells. The tumor cells absorb the radioactive material from the radiopeptide and are killed.
This treatment is called a targeted therapy because it targets tumor cells while leaving healthy cells alone. Even though it is a type of radiation, the radiation exposure to healthy tissue is limited.
Why should you consider Sheba Medical Center in Israel to treat neuroendocrine tumors with PRRT?
The Neuroendocrine Unit of the Institute of Endocrinology at Sheba Medical Center is one of the few clinics in the world to offer PRRT to treat NETs. As the largest hospital in the region, Sheba treats more patients with NETs than many other medical institutions.
At The Institute of Endocrinology at Sheba, you’ll meet an experienced treatment team that is up to date on the latest research and clinical trials in the field. The physicians in the endocrinology unit collaborate with other specialists including oncologists, surgeons, cardiologists, ophthalmologists, and more in order to provide personalized treatment to each patient. Here’s why so many people are choosing Sheba to treat their neuroendocrine tumors:
- Sheba Medical Center has earned its place in the top 10 best hospitals in the world, according to Newsweek, for its advancement in medical science and biotechnical innovation.
- Sheba is fully accredited by the Joint Commission International (JCI), awarding the hospital for what is considered the gold standard in global healthcare.
- Sheba Medical Center and MD Anderson Cancer Center in the US are close partners and often share research and staff with one another.
- The Institute of Endocrinology at Sheba features a world-renowned team of specialists including Dr. Amit Tirosh, the Head of Neuroendocrine Tumors Services at the Institute of Endocrinology. Dr. Tirosh provides patients with NETs with the latest treatments, such as PRRT, and is actively researching the bioinformatics of endocrine cancer.
- The price of PRRT in Israel is significantly lower than it is in the US and in other medical institutions. As a government institution, Sheba has full price transparency, so you’ll never be surprised by hidden costs.